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Objectives. This prospective ancillary study was conducted to 
determine the association between the time from symptom onset 
to treatment and cardiac rupture in patients with acute myocar- 
dial infarction. 
Background. There is strong evidence that the time window for 
thrombolytic therapy should be extended to at least 12 h; however, 
many clinicians are concerned that late treatment may cause an 
excessive occurrence of death from cardiac rupture. Because up to 
30% of patients with acute myocardial infarction arrive in the 
hospital >6 h from symptom onset, resolving this issue is of 
paramount clinical importance. 
Methods. A total of 5,711 patients with acute myocardial 
infarction were randomized to receive intravenous recombinant 
tissue-type plasminogen activator (rt-PA) (100 mg over 3 h) or 
matching placebo, within 6 and 24 h from symptom onset. Both 
groups received immediate oral aspirin, and a majority of patients 
received intravenous heparin during the initial 48 h. 
Results, By 35 days, 177 patients had died, with the cause of 
death specified as cardiac rupture (53 patients), electromechani- 
cal dissociation (42 patients) or asystole (82 patients). An addi- 
tional 370 patients had died of other causes. In patients treated 
within 12 h, the proportion of rupture deaths in the group given 
rt-PA was higher than that observed in those who received 
placebo, but the difference was not statistically significant. In 
patients treated after 12 h, there was no evidence of an increased 
incidence of rupture with rt-PA, and the proportion of deaths due 
to rupture in this group was lower than that in patients given 
placebo. However, there was evidence of a difference between rt-PA 
and placebo with respect to the time that rupture became clini- 
cally manifest (treatment by time to death interaction, p = 0.03). 
Conclusions. This study provides unequivocal evidence that late 
treatment (6 to 24 h after symptom onset) with rt-PA is not 
associated with an increased risk of cardiac rupture. However, for 
reasons that are unclear, coronary thrombolysis appears to 
accelerate rupture events, typically to within 24 h of treatment. 
(J Am Coil Cardiol 1995;25:1063- 8) 
Several arge-scale clinical trials (1-5) have demonstrated 
that thrombolytic therapy improves urvival among patients 
with acute myocardial infarction. Although the benefits 
derived from late thrombolysis are less certain, emerging 
evidence suggests trongly that the time window for treat- 
ment should be extended to at least 12 h (5-7). The Late 
Assessment of Thrombolytic Etficacy (LATE) study, a ran- 
domized, double-blind trial of 5,711 patients with symptoms 
and electrocardiographic (ECG) criteria consistent with 
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acute myocardial infarction, demonstrated a 25% mortality 
reduction in favor of treatment with recombinant tissue-type 
plasminogen activator (rt-PA) and suggested that some 
patients may benefit even when treated >12 h after symp- 
tom onset (7). Current enthusiasm for late thrombolysis has 
been tempered somewhat by ongoing concern that it in- 
creases the risk of cardiac rupture. Although data from 
randomized clinical trials supporting this contention are not 
available, the findings of a recta-analysis performed by 
Honan and colleagues (8) are widely quoted. In their report, 
the odds ratio of cardiac rupture correlated irectly with 
time to treatment. Further support may be found in the 
observations made by the Fibrinolytic Therapy Trialists' 
collaborative group (9), which cited an "early hazard" 
among patients treated with thrombolytic agents after 12 h 
from symptom onset. The purpose of our study was to 
examine, in a prospectively designed LATE ancillary study, 
the incidence of cardiac rupture as a cause of death in 
patients with myocardial infarction treated with rt-PA or 
matching placebo between 6and 24 h after symptom onset. 
©1995 by the Amcrican Collcge of Cardiology 0735-1097/95/$9,5(l 
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Methods 
The methods employed, participating centers and investi- 
gators in the LATE study have been described previously (7). 
Briefly, the trial was performed in 230 centers (Australia 35, 
Canada 21, Europe 146, United States 28) beginning in April 
1989 and ending in February 1992. Patients >18 years of age 
were considered for study entry if they fulfilled the following 
criteria: 1) They had chest pain of suspected cardiac origin 
lasting ->30 rain. 2) An ECG exhibited one or more of the 
following: ST elevation ->0.1 mV in two or more limb leads or 
->0.2 mV in two or more chest leads, ST depression ->0.2 mV 
in at least two leads and thought o represent a non-Q wave 
infarction. Patients with old or equivocal ECG changes or 
bundle branch block were considered for study entry in the 
presence of elevated serum cardiac enzyme levels. 3) Treat- 
ment could be initiated 6 to 24 h after symptom onset. 
Exclusion criteria were as follows: serious bleeding within the 
previous 6 months, a history of stroke, a transient ischemic 
attack or neurosurgery within the previous 6 months, major 
surgery or trauma within the previous month, shock with 
systolic blood pressure <80 mm Hg, hypertension (blood 
pressure >200 mm Hg systolic or 110 mm Hg diastolic not 
controlled within the 6- to 24-h time window) and inability to 
give informed consent or comply with the protocol. 
Randomization and treatment. Patients were treated with 
intravenous rt-PA (Alteplase, Genentech, Inc.), given as a 
10-rag bolus and a 50-rag infusion over 1 h followed by 20 nag 
in each of the next 2 h, or matching placebo. All patients 
received aspirin on study entry and 75 to 360 mg daily for the 
duration of follow-up. The use of heparin was at the discretion 
of the investigators, but intravenous heparin use during the 
initial 48 h was encouraged either as 1) an initial 5,000-U bolus 
before administration of the study drug, a second bolus of 
5,000 U on completion of administration of the study drug 
followed by 1,000 U/h, or 2) an initial bolus of 5,000 U before 
administration of the study drug followed immediately by a 
continuous infusion of 1,000 U/h. All other medications and 
intravenous therapies were at the discretion of the participat- 
ing physicians, with the exception of oral beta-adrenergic 
blocking agents, which were strongly recommended. 
Adverse events. Details of all deaths were given and the 
primary cause was identified by the admitting physician. This 
information was scrutinized in blinded manner by the interna- 
tional study coordinator, and the cause of death was catego- 
rized as 1 of 24 possible causes on the basis of the information 
provided. Where specifically indicated, these included cardiac 
rupture, electromechanical dissociation or asystole. Because 
postmortem examinations were not mandatory for deaths 
within the LATE study, precise identification of all cardiac 
rupture vents was not possible. Because it can be argued that 
cardiac rupture is implicated in many deaths attributed to 
electromechanical dissociation and asystole, this combined 
group of outcomes was considered in the first instance (10). 
Statistical methods. Differences among the groups of pa- 
tients who died of cardiac rupture, those who died of other 
Table 1. Patient Groups in the LATE Study: 
Baseline Characteristics 
Death From 
Cardiac Rupture, Death From Alive at 
EMD, Asystole Other Causes 35 Days p 
(n - 177) (n = 370) (n - 5,164) Value* 
Age (yr) 69.8 + 8.4 70 _+ 8.4 61.9 _+ 10.8 < 0.0001 
Male (%) 62.1 61.9 73.5 < 0.0001 
MI (%) 
Q wave 76.8 70 59.2 < 0.001 
Non-O wave 14.1 20 23.4 
Anterior 48 48.9 39.4 < 0.0001 
Inferior 23.7 24.1 34.2 
Previous 21.5 31.1 20.9 < 0.0001 
Recurrent 7.9 18.4 3.1 < 0.0001 
Active smoker (%) 27.1 25.7 42.4 < 0.0001 
Weight (kg) 72.1 _+ 12.4 73.2 2 13.4 76.5 _+ 13.8 < 0.0001 
NYHA class (%) 
I 24.3 27.3 36 < 0.0001 
II 37.3 3(I.3 41.6 
lll 37.9 42.2 22.3 
Time to bolus of 14.4 ± 5.2 14.4 + 5.3 14.8 _+ 5.3 0.2803 
rt-PA or placebo 
Heparin (%) 54.8 55.4 65.2 < 0.0001 
* p value represents comparison of all three groups. Data are presented as 
percent of patients or mean value _+ SD. EMD electromechanical dissociation; 
LATE Late Assessment ofThrombolytic Efficacy; M1 myocardial infarction; 
NYHA class - New York Heart Association functional class; rt-PA = recom- 
binant tissue-type plasminogen activator. 
causes and those who were alive at 35 days were assessed by 
using analysis of variance techniques for continuous variables, 
logistic regression for two-level factor variables and log-linear 
models for multilevel factor variables. In each analysis, the 
comparison for all three groups was made by fitting both 
the main effects model and the null model and assessing the 
change in deviance. The separate comparisons ofpatients who 
died of rupture with those who died of other causes and with 
those who were alive were made by considering the ratio of the 
estimate of the appropriate coefficient with its standard error 
in the main effects model. Comparison of deaths due to 
rupture versus other deaths, taking into consideration the 
treatment received and the time of onset of treatment, were 
made by using logistic regression. 
Results 
A total of 5,711 patients were enrolled in the LATE study. 
By 35 days, 175 of these patients had died of a cause specified 
as cardiac rupture (n = 51), electromechanical dissociation 
(n = 42), or asystole (n = 82). Two other patients, who were 
classified as having had a recurrence of infarction in the 
hospital are considered with the group that died of rupture, 
bringing the total to 177. An additional 370 patients had also 
died by 35 days. Overall, 5,164 patients were alive at 35 days. 
Differences among the groups with respect o baseline 
characteristics are presented inTable 1. The patients who died 
of cardiac rupture did not differ from those who died of other 
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causes in terms of age, gender, confirmed iagnosis, site of 
infarction, body weight, New York Heart Association func- 
tional class and smoking history. As expected, however, there 
were large differences in each instance between the group that 
died of rupture and those who were alive at 35 days. Patients 
who died of rupture were more likely to have experienced a Overallt 
prior infarction or to have had a recurrent infarction than were < 12 h 
those who died of other causes, rt-PA 
Placebo Table 2 considers differences between rt-PA and placebo >12 h 
for patients treated -<12 or >12 h from symptom onset, rt-PA 
comparing deaths due to rupture with all deaths. Among Placebo 
patients treated within 12 h, the proportion of deaths attribut- ST elevation 
able to rupture was higher in the rt-PA group than in the -<12 h 
placebo group, whereas for those treated after 12 h, the rt-PA 
proportion of deaths due to rupture was lower in the rt-PA Placebo 
group. There was no evidence of an interaction between >12 h 
rt-PA 
treatment and time to treatment. There was modest evidence Placebo 
of a treatment by time to treatment interaction for the num-  Heparin 
ber of deaths due to rupture compared with all deaths in the -<12 h 
group of patients with ST elevation (p = 0.0809). For the other rt-PA 
groups considered, patients treated with or without adjunctive Placebo 
heparin therapy and those treated -<3 or >3 h from admission, >12 h 
there was no evidence of interaction effect. There was no rt-PA 
Placebo 
evidence that late therapy (>12 h) increased the likelihood of No heparin 
rupture in any subgroup. -<12 h 
Treatment with rt-PA was not associated with significant rt-PA 
increases in the incidence of rupture either in those patients Placebo 
who received heparin or in those who did not. However, it is >12 b 
not possible with these data to determine whether treatment rt-PA 
Placebo with heparin is itself associated with more rupture events. 
Delay time:]: <-3 h 
Heparin therapy was not randomized, and it is not clear and <-12 h 
indeed unlikely that the group receiving heparin was directly rt-PA 
comparable to the group that did not receive heparin. Placebo 
Table 3 indicates the day of occurrence of each case of >t2 h 
rupture, electromechanical dissociation or asystole, consider- rt-PA 
ing all patients and those treated with rt-PA within or after Placebo 
12 h. A logistic regression analysis considering those who died Delay time:) >3 h 
-<12 h 
of rupture and those who died of other causes was performed rt-PA 
on the overall results to determine whether there was a Placebo 
significant reatment by time to death interaction effect, and a 712 h 
significant interaction was observed (p = 0.0346). Hence, the rt-PA 
time of onset of rupture after rt-PA therapy was different from Placebo 
that after placebo therapy. The occurrence of rupture in the 
rt-PA group was in general earlier; hence, it can be said that 
rt-PA therapy accelerates the onset rather than increases the 
frequency of cardiac rupture. 
Table 2. Mortality in Patients According to Time to Treatment 
(~12 or >12 h), Other Treatment Variables and Cause of Death 
Deaths From Cardiac 
Rupture, EMD, Total p 
Asystole Deaths Value* 
























*p value represents est for treatment by time to treatment interaction. 
t There were 25 patients (including 9 who died) who did not start treatment or 
who did not have data indicating whether they were treated at <12 h or >12 h 
after symptom onset. ~ Delay time from hospital arrival to treatment. Abbrevi- 
ations as in Table 1. 
Discussion 
The importance of myocardial salvage and improved pa- 
tient survival achieved by successful coronary thrombolysis 
represent major advances in the management of acute myo- 
cardial infarction. However, there is compelling evidence that 
late reperfusion also favorably affects clinical outcome (7,11- 
14). Because >30% of patients with myocardial infarction seek 
medical care between 6 and 24 h after symptom onset, it is of 
utmost importance to establish firmly the risks and benefits of 
late thrombolysis. Although widespread concern has been 
raised about cardiac rupture, our findings--obtained in the 
largest study to examine the benefit of thrombolysis for 
patients treated 6 to 24 h from symptom onset--suggest 
strongly that late administration f thrombolytic therapy is not 
associated with an increased risk of this predominantly fatal 
event. 
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Table 3. Patient Deaths From Cardiac Rupture, Electromechanical 
Dissociation orAsystole According to Time to Treatment 
All Patients 
Time to Time to 
Treatment Treatment 
-<12 Hours >12 Hours 
Cause of Death rt-PA Placebo rt-PA Placebo rt-PA Placebo 
*Rupture, EMD or 
asystole (combined) 
Total 79 98 34 40 43 56 
Day 0-1 43 29 19 14 23 13 
Day 2-7 3{) 49 13 21 16 28 
Day 8-35 6 2{) 2 5 4 15 
Rupture only 
Total 29 24 15 10 13 12 
Day 0-1 18 5 9 2 8 1 
Day 2-7 10 17 5 7 5 10 
Day 8-35 1 2 1 1 0 1 
EMD only 
Total 16 26 8 12 8 14 
Day 0-1 7 13 3 7 4 6 
Day 2-7 9 l0 5 5 4 5 
Day 8-35 0 3 0 0 0 3 
Asystole only 
Total 34 48 11 18 22 30 
Day 0-1 18 I I 7 5 11 6 
Day 2-7 11 22 3 9 7 13 
Day 8-35 5 15 1 4 4 ll 
*There were 25 patients (including 9who died) for whom treatment was not 
started or it was not possible to determine if they were treated <12 h or >12 h 
after symptom onset. Abbreviations as in Table 1. 
Mechanisms of cardiac rupture. Cardiac rupture is a cat- 
astrophic omplication of acute myocardial infarction respon- 
sible for 5% to 20% of all in-hospital deaths (15-19). It can 
take several forms, including free wall rupture, ventricular 
pseudoaneurysm formation, ventricular septal rupture, papil- 
lary muscle rupture and, less frequently, atrial rupture. In the 
prethrombolytic era, rupture usually occurred in the 1st 2 
weeks after infarction with a peak incidence at 5 days (20,21). 
In contrast, cardiac rupture now may be accelerated by throm- 
bolysis and coronary reperfusion. 
There is firm evidence that transmural infarction is a 
prerequisite for cardiac rupture (20,22). In nontransmural 
infarction, the wave of necrosis that commonly extends from 
the endocardial tothe epicardial surface in transmural infarc- 
tion is arrested, leaving a shell of viable subepicardium. This 
shell, containing normal structural components and mechani- 
cal properties, may offer resistance to rupture. Thus, early 
successful thrombolysis and myocardial salvage would be ex- 
pected to decrease the overall risk of rupture (23). 
Myocardial hemorrhage, dissecting into an area of infarction, 
may contribute to cardiac rupture. In the prethrombolytic era 
most infarctions were described as anemic under gross or micro- 
scopic examination (24,25). In contrast, reperfusion achieved by 
thrombolysis (26) typically causes hemorrhagic infarction that is 
most pronounced in areas of extensive myocardial necrosis (27- 
29). Systemic anticoagulation with heparin could, at least theo- 
retically, increase the overall extent of myocardial hemorrhage. In 
our study, heparin administration failed to influence the incidence 
of cardiac rupture in patients treated with rt-PA. However, 
because treatment with heparin was not randomized inthe LATE 
study, it is difficult to draw firm conclusions about he effect of this 
agent (or anticoagulation in general). 
At autopsy, hearts with rupture have been shown to have a 
virtual absence of collagen at the involved site (30,31). Dimi- 
nution of collagen begins almost immediately after infarction 
and may be mediated by collagenases (32). Plasmin, a nonspe- 
cific proteolytic enzyme generated by all thrombolytic agents, 
increases collagen breakdown both through direct mechanisms 
and by activating latent issue collagenases (33). Late throm- 
bolysis could increase collagen breakdown at the time when 
neutrophil-mediated collagenase activity has already begun to 
weaken the supporting fibroskeleton (34), thereby predispos- 
ing to rupture. However, in this randomized, placebo- 
controlled trial of >5,000 patients, we were unable to show 
increasing risk for rupture with late thrombolysis, even in those 
who received treatment up to 24 h after symptom onset. 
Previous studies. The GISSI-I trial (2), which entered 
patients with symptoms of myocardial infarction up to 12 h 
after symptom onset, reported a significantly higher rate of 
cardiac rupture among late entry patients treated with strep- 
tokinase (35). In a meta-analysis (8) including 58 patients with 
cardiac rupture among 1,638 patients from four trials, cardiac 
rupture directly correlated with time to treatment. The odds 
ratio for rupture was 0.4 at 7 h, 0.93 at 11 h and 3.21 at 17 h. 
An analysis of 4,692 deaths among 44,346 patients from 42 
clinical trials demonstrated that the odds ratio of death was 
also directly correlated with time to treatment: 0.72 at 3 h, 0.88 
at 14 h and 1.00 at 21 h. The conclusions drawn were that late 
treatment increased the risk of cardiac rupture but that 
thrombolytic therapy still offered overall benefit even when 
given as late as almost 24 h after symptom onset. Our findings 
in the LATE study support the hypothesis that the time 
window for thrombolysis with rt-PA should be extended to at 
least 12 h and possibly longer in selected patients. However, we 
were unable to show that cardiac rupture increases with 
treatment initiated after 12 h. There are several potential 
reasons for this negative finding. First, our study included 5,711 
patients randomized to receive either rt-PA or placebo be- 
tween 6 and 24 h after symptom onset. Unlike meta-analyses 
that use average time to treatment for groups of patients, we 
evaluated individual patients with suspected cardiac rupture. It 
is therefore likely that we were able to assess the effect of time 
to treatment on risk with greater precision. Second, rt-PA was 
the thrombolytic agent used in the LATE study. In contrast, 
streptokinase was the thrombolytic agent used in GISSM and 
in each of the four clinical trials included in the meta-analysis 
of Honan et al. (8). Although this concept has not previously 
been explored, it is possible that if the systemic lytic state 
contributes to cardiac rupture, nonselective thrombolytic 
agents may ultimately pose a greater risk than that of selective 
agents. We are currently investigating this possibility. 
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Limitations of the study. To increase the likelihood of 
including all potential cases of cardiac rupture, we included 
patients with electromechanical dissociation and asystole in the 
final analysis. It is therefore possible that we overestimated 
the actual occurrence of rupture. This possibility is balanced by 
the likelihood that we missed cardiac rupture in some patients 
without arrhythmia stigmata or autopsy; such patients are, in 
fact, highly likely to confound the data because of miscatego- 
rization. We analyzed the data by individual diagnosis (rup- 
ture, electromechanical dissociation or asystole) as well as by 
their composite. The findings were essentially unchanged. 
Although cardiac rupture was not an autopsy-confirmed diag- 
nosis in each case, the similar autopsy rates and consistent 
classification criteria in the groups given rt-PA and placebo 
make it highly unlikely that a reporting bias influenced our 
results. 
The LATE study, similar to other large scale clinical trials 
(2,10,35), grouped cardiac deaths into those resulting from 
nonmechanical failure (rupture, electromechanical dissocia- 
tion, asystole) and those related directly to mechanical failure 
(shock, left ventricular failure, respiratory arrest). The decision 
to group cardiac rupture, electromechanical dissociation and 
asystole together represents a precedent set by the ISIS-I 
investigators (10). Clearly, it is not possible to obtain detailed 
pathologic onfirmation in each suspected case of rupture in 
clinical trials including thousands of patients. A broader defi- 
nition is preferred and allows greater applicability of the 
findings. 
Conclusions and clinical implications. There is unequivo- 
cal evidence that early coronary thrombolysis mproves urvival 
in patients with myocardial infarction. The evidence is also 
strong that late treatment, up to and in some instances after 
12 h from symptom onset, may offer significant benefit as well. 
Despite previous concerns, the findings of our prospectively 
designed study show conclusively that late treatment does not 
increase the incidence of cardiac rupture. However, they do 
suggest hat the time course of rupture may be accelerated by 
thrombolysis. Although the present study was not designed to 
explore mechanisms, it seems plausible that successful reper- 
fusion may accelerate rupture of type I (abrupt slitlike tear) or 
type II (erosion of the infarct zone) ruptures, while decreasing 
type III events (characterized by early aneurysm formation 
(18). Clearly, this area warrants further investigation. 
References  
1. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis m 
acute myocardial nfarction: limitation ofinfarct size and improved survival. 
J Am Coil Cardiol 1986;7:717-28. 
2. Gruppo Italiana per Io Studio della Stretochinasi Nell'infarcto Miocardico 
(GISSI). Effectiveness of intravenous thrombolytic reatment i  acute myo- 
cardial infarction. Lancet 1986;1:397-402. 
3. Wilcox RG, Olsson CG, Skene AM, ct al. For the ASSET Study Group. Trial 
of tissue plasminogen activator for mortality reduction i acute myocardial 
infarction. Lancet 1988;1:525-30. 
4. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after 
acute myocardial infarction: preliminary eport of a placebo-controlled 
clinical trial. Lancet 1988;1:545-9. 
5. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America 
del Sur) Collaborative Group. Randomized trial of late thrombolysis in 
patients with suspected acute myocardial infarction. Lancet 1993;341:767- 
72. 
6. IS18-2 (Second International Study of Infarct Survival) Collaborative Group. 
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither 
among 17,187 cases of suspected acute myocardial nfarction. Lancet 1988; 
2:349-60. 
7. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) 
study with alteplase 6-24 hours after onset of acute myocardial infarction. 
Lancet 1993;342:759-66. 
8. Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality and 
the timing of thrombolytic herapy: a meta-analysis. J Am Coil Cardiol 
1990; 16:359 -67. 
9. Fibrinolytic Therapy Trialists (FTF) Collaborative Group. Indications for 
fibrinolytic therapy insuspected acute myocardial nfarction: a collaborative 
overview of early mortality and major morbidity results of all randomized 
trials of more than 1000 patients. Lancet 1994;343:311-22. 
10. ISIS-I Collaborative Group. Mechanisms for the early mortality reduction 
produced by beta-blockade started early in acute myocardial infarction. 
Lancet 1988;1:921-3. 
11. Braunwald E. Thrombolytic reperfusion of acute myocardial infarction: 
resolved and unresolved issues. J Am Coll Cardiol 1988;I2:85A-92A. 
12. Braunwald E.Myocardial reperfusion, limitation ofinfarct size, reduction of
left ventricular dysfunction a d improved survival: should the paradigm be 
expanded? Circulation 1989;79:441-4. 
13. Van de Weft F. Discrepancies between the effects of coronary reperfusion 
on survival nd left ventricular function. Lancet 1989;1:1367-9. 
14. Califf RM, Yopol EJ, Gersh BJ. From myocardial salvage to patient salvage 
in acute myocardial infarction: the role of reperfusion therapy. J Am Coil 
Cardiol 1989;14:1382-8. 
15. Lewis AJ, Burchell HB, Titus JL. Clinical and pathologic features of 
post-infarction cardiac rupture. Am J Cardiol 1969;23:43-53. 
16. Shapira I, lsakov A, Burke M, Almog CH. Cardiac rupture in patients with 
acute myocardial nfarction. Chest 1987;92:219-23. 
17. Rasmussen S, Leth A, Kjoller E, Pedersen A. Cardiac rupture in acute 
myocardial infarction. Acta Med Scand 1979;205:11 6.
18. Pohjola-Sintonen S, Muller JE, Stone PH, et al. Ventricular septal and free 
wall rupture complicating acute myocardial infarction: experience in the 
Multicenter Investigation f Limitation of Infarct Size. Am Heart J 1989; 
117:809-18. 
19. Becket AE, Van Mantgem JP. Cardiac tamponade: a study of 5O hearts. Eur 
J Cardiol 1975;3/4:359-71. 
20. Lautsch E, Lanks KW. Pathogenesis of cardiac rupture. Arch Pathol 
1976:84:264 -71. 
21. Batts KP, Ackermann DM, Edwards WD. Post-infarction rupture of the left 
ventricular free wall: clinicopathologic correlates in 100 consecutive autopsy 
cases. Hum Pathol 1990;21:530-5. 
22. Wessler S, Zoll PM, Schlesinger MJ. The pathogenesis of spontaneous 
cardiac rupture. Circulation 1952;6:334-51. 
23. Gertz SD, Kragel AH, Kalan JM, et al. Comparison of coronary and 
myocardial morphologic f ndings in patients with and without thrombolytic 
therapy during fatal first acutc myocardial nfarction. Am J Cardiol 1990;66: 
904-9. 
24. Fujwara H, Onodera T, Tanaka M, et al. Therapy and prevention. Coronary 
thrombolysis. A clinicopathologic study of patients with hemorrhagic myo- 
cardial infarction treated with selective coronary thrombolysis with uroki- 
nase. Circulation 1986;73:4:749 57.
25. Waller BF. The pathology, ofacute myocardial nfarction: definition, loca- 
tion, pathogenesis, effects of reperfusion, complications, and sequelae. 
Cardiol Clin 1988;6:1-28. 
26. Yasuno M, Edno S, Takahashi M, et aL Angiographic and pathologic 
evidence of hemorrhage into the myocardium after coronary reperfusion 
angiology. AngioloD' 1984;35:797-801. 
27. Richardson SG, Callen D, Morton P, et al. Pathological changes after 
intravenous streptokinase tr atment in eight patients with acute myocardial 
infarction. Br Heart J 1989;61:390-5. 
28. Mathey DG, Schofer J, Kuck KH, Beil U, Kloppel G. Transmural hemor- 
rhagic myocardial infarction after intracorona~ streptokinase: clinical, an- 
giographic, and necropsy findings. Br Heart J 1982;48:546-51. 
29. Higginson LAJ, White F, Heggtveit HA, et aL Determinants of myocardial 
1068 BECKER ET AL. JACC Vol. 25, No. 5 
CARDIAC RUPTURE AND THROMBOLYTIC THERAPY April 1995:1063-8 
hemorrhage after coronary_ reperfusion i  the anesthestized dog. Circulation 
1982;65:62-9. 
30. Factor SM, Robinson TF, Dominitiz R, Cho S. Alterations of the myocardial 
skeletal framework in acute myocardial infarction with and without 
ventricular upture: a preliminary report. Am J Cardiovasc Pathol 
1986;1:91-7. 
3 I. Factor SM, Robinson TF, Dominitz R, Cho S. Alterations of the myocardial 
skeletal framework in acute myocardial infarction with and without ventric- 
ular rupture. Am J Cardiovasc Pathol 1986;1:91-7. 
32. Wittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial 
infarct expansion. Circulation 1991 ;84:2123-34. 
33. Peuhkurinen K J, Risteli L, Melkko JT, et al. Thrombolytic therapy with 
streptokinase timulates collagen breakdown. Circulation 1991;83:1969-75. 
34. Dreyer WH, Michael LH, West MS, et al. Neutrophil accumulation i  
ischemic anine myocardium. Circulation 1991 ;84:400-11. 
35. Mauri F, DeBiase AM, Franzosi MD, Pampallona S, Foresti A, Gasparini M. 
GISSI analisis dclle cause di morte intraspedaliera. G Ital Cardiol 1987;17: 
37-44. 
